{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:07:33Z","timestamp":1789189653125,"version":"build-2803163510"},"reference-count":17,"publisher":"Editorial Committee of Annals of Thoracic and Cardiovascular Surgery","issue":"1","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K10520"],"award-info":[{"award-number":["JP16K10520"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ATCS","Ann Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5761\/atcs.oa.26-00142","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:11:34Z","timestamp":1788991894000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases"],"prefix":"10.5761","volume":"32","author":[{"given":"Takashi","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-9690","authenticated-orcid":false,"given":"Satoshi","family":"Yajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Gastroenterology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Taniyama","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ohkura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsubosa","sequence":"additional","affiliation":[{"name":"Division of Esophageal Surgery, Shizuoka Cancer Center, Suito-gun, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3757","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Weigl K, Thomsen H, Balavarca Y, et al. Genetic risk score is associated with prevalence of advanced neoplasms in a colorectal cancer screening population. Gastroenterology 2018; 155: 88\u201398.","DOI":"10.1053\/j.gastro.2018.03.030"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today 2020; 50: 12\u201320.","DOI":"10.1007\/s00595-019-01878-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group study\u2014JCOG9204. J Clin Oncol 2003; 21: 4592\u20136.","DOI":"10.1200\/JCO.2003.12.095"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012; 19: 68\u201374.","DOI":"10.1245\/s10434-011-2049-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000; 89: 1677\u201383.","DOI":"10.1002\/1097-0142(20001015)89:8<1677::AID-CNCR5>3.3.CO;2-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ralhan R, Arora S, Chattopadhyay TK, et al. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 2000; 85: 791\u20135.","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<791::AID-IJC9>3.0.CO;2-K"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Suzuki T, Yajima S, Okamura A, et al. Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study. Esophagus 2021; 18: 65\u201371.","DOI":"10.1007\/s10388-020-00761-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yamashita K, Makino T, Tanaka K, et al. Peritherapeutic serum p53 antibody titers are predictors of survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy and surgery. World J Surg 2017; 41: 1566\u201374.","DOI":"10.1007\/s00268-017-3894-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hiyoshi Y, Yoshida N, Watanabe M, et al. The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) in esophageal squamous cell carcinoma. World J Surg 2017; 41: 480\u20136.","DOI":"10.1007\/s00268-016-3649-0"},{"key":"10","unstructured":"10) James D, Mary KG, Wittekind CH. UICC TNM classification of malignant tumors. 8th ed. John Wiley &amp; Sons Inc: NY; 2017."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 2003; 97: 682\u20139.","DOI":"10.1002\/cncr.11092"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shimada H, Kitabayashi H, Nabeya Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003; 133: 24\u201331.","DOI":"10.1067\/msy.2003.31"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Shimada H. p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2018; 2: 266\u201373.","DOI":"10.1002\/ags3.12179"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 2013; 48: 452\u20138.","DOI":"10.1038\/bmt.2012.244"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 2009; 33: 272\u20137.","DOI":"10.1007\/s00268-008-9821-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Okamura A, Matsuda S, Mayanagi S, et al. Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021; 28: 1209\u201316.","DOI":"10.1245\/s10434-020-08716-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Shimada H, Shimizu T, Ochiai T, et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001; 31: 597\u2013604.","DOI":"10.1007\/s005950170093"}],"container-title":["Annals of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/32\/1\/32_oa.26-00142\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:34:50Z","timestamp":1789187690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/32\/1\/32_oa.26-00142\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5761\/atcs.oa.26-00142","relation":{},"ISSN":["1341-1098","2186-1005"],"issn-type":[{"value":"1341-1098","type":"print"},{"value":"2186-1005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"oa.26-00142"}}